| Literature DB >> 24145143 |
M Braceland1, R Bickerdike, J Tinsley, D Cockerill, M F Mcloughlin, D A Graham, R J Burchmore, W Weir, C Wallace, P D Eckersall.
Abstract
Salmonid alphavirus is the aetological agent of pancreas disease (PD) in marine Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, with most outbreaks in Norway caused by SAV subtype 3 (SAV3). This atypical alphavirus is transmitted horizontally causing a significant economic impact on the aquaculture industry. This histopathological and proteomic study, using an established cohabitational experimental model, investigated the correlation between tissue damage during PD and a number of serum proteins associated with these pathologies in Atlantic salmon. The proteins were identified by two-dimensional electrophoresis, trypsin digest and peptide MS/MS fingerprinting. A number of humoral components of immunity which may act as biomarkers of the disease were also identified. For example, creatine kinase, enolase and malate dehydrogenase serum concentrations were shown to correlate with pathology during PD. In contrast, hemopexin, transferrin, and apolipoprotein, amongst others, altered during later stages of the disease and did not correlate with tissue pathologies. This approach has given new insight into not only PD but also fish disease as a whole, by characterisation of the protein response to infection, through pathological processes to tissue recovery. BIOLOGICAL SIGNIFICANCE: Salmonid alphavirus causes pancreas disease (PD) in Atlantic salmon, Salmo salar, and has a major economic impact on the aquaculture industry. A proteomic investigation of the change to the serum proteome during PD has been made with an established experimental model of the disease. Serum proteins were identified by two-dimensional electrophoresis, trypsin digest and peptide MS/MS fingerprinting with 72 protein spots being shown to alter significantly over the 12week period of the infection. The concentrations of certain proteins in serum such as creatine kinase, enolase and malate dehydrogenase were shown to correlate with tissue pathology while other proteins such as hemopexin, transferrin, and apolipoprotein, altered in concentration during later stages of the disease and did not correlate with tissue pathologies. The protein response to infection may be used to monitor disease progression and enhance understanding of the pathology of PD.Entities:
Keywords: 2-Dimension electrophoresis; Alpha virus; Atlantic salmon; Biomarkers; Pathology; Serum proteome
Mesh:
Substances:
Year: 2013 PMID: 24145143 PMCID: PMC3878379 DOI: 10.1016/j.jprot.2013.10.016
Source DB: PubMed Journal: J Proteomics ISSN: 1874-3919 Impact factor: 4.044
The percentage of samples from salmon sampled at each time point that gave positive results for SAV infection detected by reverse transcriptase polymerase chain reaction (RT-PCR), virus identification (SAV) and virus neutralisation (VN). Where ‘–’ indicates that testing was not carried out.
| Sampling time point | Positive samples (% of total) | ||
|---|---|---|---|
| RT-PCR | SAV | VN | |
| W0 | – | 0 | 0 |
| W2 | 75 | – | – |
| W3 | 87 | – | – |
| W4 | 97 | 13 | 27 |
| W5 | 88 | 2 | 67 |
| W6 | – | – | – |
| W8 | – | – | – |
| W10 | – | – | – |
| W12 | – | – | – |
Fig. 1Histopathological scoring of mean lesion scores in relation to week post challenge with SAV in pancreas (Pan), heart (HT), red muscle (RM) and white muscle (WM) of salmon (n = 9 per time point).
Fig. 2Sample images of 2-dimension electrophoresis gels from all sampling time points from week 0 to 12 post challenge. From left to right: Top row = Week 0, 2 and 3 images. Middle row = Week 4, 5 and 6 images. Bottom row = Week 8, 10 and 12 images.
Fig. 3Protein spots identified on 2-dimension electrophoresis as being as being differentially expressed following infection superimposed on a week 0 image. Molecular weight (MW) is indicated on protein standard ladder in kilodalton (kD) and isoelectric point (pI) range also shown.
Protein spots showing maximum fold increase in spot intensity during the 12 weeks post infection, where negative symbol (-) indicates a fold decrease in spot intensity, compared to pre-infection on week 0.
| Spot Number | Identification (Uniprot Reference) | Max. Fold Change | Estimated pI | Estimated MW (kD) | MOWSE Score | Peptide Matches | % coverage |
|---|---|---|---|---|---|---|---|
| 19 | Serotransferrin II + Ig heavy chain C region (TRF2SALSA + | 3.1 | 6.91 | 112 | 821, 65 | 43, 2 | 38, 5 |
| 32 | C1 inhibitor ( | 5.4 | 5.21 | 97 | 137 | 6 | 14 |
| 43 | Serotransferrin II (TRF2SALSA) | 4.5 | 7.36 | 91 | 527 | 14 | 19 |
| 45 | Complement factor H ( | 10.4 | 8.37 | 91 | 79 | 2 | 3 |
| 47 | Alpha-2 enolase-1 + Complement factor H ( | 3.2 | 7.52 | 90 | 111, 94 | 3, 3 | 9, 3 |
| 74 | No significant identification | 4.4 | 4.33 | 81 | |||
| 98 | Apolipoprotein A-I precursor (JH0472) | 2.6 | 4.96 | 76 | 113 | 5 | 23 |
| 146 | Complement component C9 ( | 2.2 | 5.2 | 70 | 226 | 7 | 17 |
| 150 | Hemopexin-like protein ( | 9.6 | 4.22 | 68 | 64 | 3 | 9 |
| 151 | Transferrin + Ig heavy chain C region (T11749 + A46533) | 1.5 | 7.27 | 68 | 967, 139 | 32, 4 | 35, 12 |
| 201 | Antithrombin + Complement component C9 ( | - 2.8 | 5.43 | 59 | 156, 196 | 8, 6 | 14, 21 |
| 220 | Hemopexin-like protein + Beta-actin ( | 2.5 | 6.57 | 57 | 166, 107 | 3, 3 | 8, 12 |
| 224 | Hemopexin-like protein ( | 2.2 | 7.5 | 56 | 150 | 7 | 16 |
| 227 | Hemopexin-like protein ( | 1.5 | 6.06 | 56 | 128 | 11 | 14 |
| 249 | Serotransferrin II (TRF2SALSA) | 5.4 | 8.36 | 51 | 101 | 3 | 7 |
| 260 | Serum albumin 2 + Serum albumin 1 (ABONS2 + ABONS1) | - 1.7 | 4.77 | 50 | 364, 320 | 14, 13 | 24, 20 |
| 299 | Enolase ( | 5 | 8.03 | 47 | 308 | 14 | 25 |
| 313 | Pyruvatekinase ( | 3.5 | 7.58 | 46 | 155 | 6 | 11 |
| 317 | Alpha-2 enolase-1 ( | 7.6 | 7.94 | 45 | 648 | 37 | 53 |
| 326 | Alpha-2 enolase-1 ( | 5.6 | 7.78 | 45 | 560 | 23 | 42 |
| 328 | Alpha-2 enolase-1 ( | 5.2 | 7.27 | 44 | 292 | 15 | 39 |
| 342 | Serum albumin 2 (ABONS2) | - 11.1 | 5.54 | 44 | 666 | 32 | 31 |
| 357 | Serum albumin 2 + Complement factorB/C2-B (ABONS2 + | 2.4 | 5.2 | 41 | 13, 3 | 18, 3 | |
| 360 | Alpha-2 enolase-1 ( | 15.3 | 7.77 | 41 | 624 | 28 | 44 |
| 368 | Serum albumin 2 + Serum albumin 1(ABONS2 + ABONS1) | - 2.8 | 4.88 | 40 | 318, 295 | 15, 13 | 19, 16 |
| 381 | Alpha-2 enolase-1 + Creatine kinase ( | 2.8 | 7.28 | 38 | 704, 101 | 30, 5 | 28, 14 |
| 386 | Aldolase ( | 13.8 | 8.72 | 38 | 108 | 3 | 23 |
| 388 | Aldolase ( | 8.1 | 8.62 | 38 | 94 | 1 | 9 |
| 391 | Muscle-type creatine kinase CKM1 ( | 5.1 | 7.35 | 38 | 252 | 9 | 17 |
| 393 | Glyceraldehyde3-phosphate dehydrogenase ( | 15.7 | 8.79 | 38 | 102 | 9 | 36 |
| 394 | Aldolase A ( | 11.8 | 8.82 | 38 | 231 | 11 | 20 |
| 395 | Serotransferrin II (TRF2SALSA) | 2.2 | 6.56 | 38 | 210 | 5 | 9 |
| 440 | Alpha-2 enolase-1(ABONS1) | 4.5 | 6.64 | 36 | 164 | 3 | 9 |
| 442 | Creatine kinase ( | 3 | 7.61 | 36 | 218 | 6 | 17 |
| 444 | Complement C3-1 + Cystein proteinase inhibitor protein ( | - 3.1 | 5.4 | 36 | 156, 36 | 10, 2 | 6, 12 |
| 450 | Serotransferrin II precursor (TRF2SALSA) | - 2.6 | 6.79 | 36 | 444 | 15 | 23 |
| 463 | Glyceraldehyde3-phosphate dehydrogenase ( | 10.6 | 8.98 | 34 | 18 | 41 | |
| 472 | Serum albumin 2 ( | - 3.7 | 4.79 | 34 | 323 | 12 | 19 |
| 473 | Fructose-bisphosphate aldolase ( | 16.9 | 8.81 | 34 | 98 | 1 | 3 |
| 477 | Aldolase A ( | 10.1 | 8.7 | 33 | 130 | 5 | 18 |
| 479 | Glyceraldehyde 3-phosphate dehydrogenase ( | 7.1 | 8.43 | 33 | 190 | 20 | 34 |
| 493 | Glyceraldehyde 3-phosphate dehydrogenase ( | 11.6 | 8.18 | 33 | 13 | 12 | |
| 494 | Glyceraldehyde 3-phosphate dehydrogenase ( | 15.3 | 8.2 | 33 | 280 | 13 | 45 |
| 499 | Proteasome ( | 8.2 | 8 | 32 | 35 | 1 | 1 |
| 500 | Aldolase A ( | 15.4 | 8.58 | 32 | 110 | 4 | 17 |
| 509 | Serotransferrin II (TRF2SALSA) | - 2.6 | 6.78 | 31 | 250 | 11 | 18 |
| 529 | Alpha-2 enolase-1 ( | 5 | 7.07 | 30 | 80 | 3 | 11 |
| 545 | Serotransferrin II (TRF2SALSA) | - 5.7 | 6.57 | 28 | 64 | 3 | 5 |
| 548 | Serum albumin 1 ( | - 7 | 6.29 | 27 | 122 | 3 | 7 |
| 556 | Serotransferrin 2 + Immunoglobulin light chain (TRF2 + AAG18369) | - 5.3 | 6.36 | 27 | 404,150 | 18, 7 | 16, 33 |
| 565 | Hemopexin-like protein ( | 7.8 | 6.26 | 26 | 51 | 4 | 8 |
| 568 | Transferrin ( | - 3.6 | 7.36 | 26 | 285 | 12 | 36 |
| 575 | Apolipoprotein A-I + Ig light chain precursor (JH0472 + AAG18369) | 1.8 | 6.62 | 26 | 188, 76 | 8, 4 | 28, 24 |
| 584 | Malatedehydrogenase1a ( | 5.8 | 8.88 | 25 | 70 | 1 | 4 |
| 586 | Apolipoprotein A-I (JH0472) | 1.9 | 4.76 | 25 | 262 | 8 | 27 |
| 598 | Apolipoprotein A-I ( | 1.5 | 5.15 | 24 | 257 | 19 | 42 |
| 602 | No significant identification. | 3.6 | 8.63 | 24 | |||
| 608 | Triosephosphate isomerase ( | 2.8 | 8.5 | 24 | 170 | 6 | 22 |
| 613 | Serum albumin 2 (ABONS2) | 2.4 | 8.1 | 24 | 488 | 19 | 23 |
| 623 | Triosephosphate isomerase + Ig light chain ( | 3.4 | 8.57 | 23 | 305, 109 | 10, 5 | 49, 19 |
| 624 | Triosephosphate isomerase ( | 2.4 | 8.1 | 23 | 194 | 11 | 50 |
| 626 | Ig light chain (AAG18369) | 2.4 | 7.26 | 23 | 190 | 8 | 24 |
| 627 | Triosephosphate isomerase + Ig light chain constant region ( | 2.6 | 7.53 | 23 | 131, 87 | 5, 4 | 22, 25 |
| 628 | Triosephosphate isomerase ( | 3.9 | 7.85 | 23 | 19 | 65 | |
| 642 | Apolipoprotein A-I ( | 3.8 | 5.57 | 21 | 435 | 27 | 37 |
| 656 | Serotransferrin II (TRF2SALSA) | - 5.3 | 8.63 | 20 | 251 | 6 | 10 |
| 668 | Apolipoprotein A-I (JH0472) | - 4.8 | 5.17 | 19 | 325 | 19 | 34 |
| 669 | Apolipoprotein A-1 (JH0472) | - 4.1 | 5.42 | 19 | 221 | 14 | 32 |
| 687 | Serotransferrin II (TRF2SALSA) | 4.6 | 7.93 | 18 | 199 | 7 | 12 |
| 702 | Prostaglandin D synthase ( | - 3.3 | 8.16 | 17 | 82 | 1 | 9 |
| 738 | Putative oncoprotein nm 23 ( | 7.2 | 7.3 | 14 | 58 | 11 | 22 |
| 741 | Nucleoside diphosphate kinase ( | 4.6 | 6.9 | 14 | 58 | 8 | 22 |
Fig. 4Arraystar heat map representing the results of Hierarchical Clustering of spot intensities. The relationships among different sampling time-points are illustrated as a dendrogram at the top of the diagram. The right-hand side gives spot number and corresponding identity from MS/MS which are grouped by profile similarity with a dendrogram showing the relationships on left-hand side. The heat map is on a colour scale where low protein abundance is represented in blue and high abundance in red.
Probability (P) of relation between change in protein spot intensity and histopathology of tissues in salmon infected with SAV.
| Probability (P) | |||||
|---|---|---|---|---|---|
| Spot number | Identification | Pancreas | Heart | Red muscle | White muscle |
| 19 | Serotransferrin II + Ig heavy chain C region (TRF2SALSA + A46533) | 0.4775 | 0.7044 | 0.642 | 0.8544 |
| 32 | C1 inhibitor ( | 0.542 | 0.3536 | 0.9656 | 0.3992 |
| 43 | Serotransferrin II (TRF2SALSA) | 0.0904 | 0.8329 | 0.204 | 0.0166 |
| 45 | Complement factor H ( | 0.3102 | 0.5645 | 0.1132 | 0.0061 |
| 47 | Alpha-2 enolase-1 + Complement factor H ( | 0.0241 | 0.7643 | 0.0663 | 0.0059 |
| 74 | No significant identification | 0.2794 | 0.5719 | 0.4255 | 0.1125 |
| 98 | Apolipoprotein A-I precursor (JH0472) | 0.2179 | 0.5856 | 0.474 | 0.1619 |
| 146 | Complement component C9 ( | 0.1032 | 0.6175 | 0.8862 | 0.9013 |
| 150 | Hemopexin-like protein ( | 0.872 | 0.3269 | 0.7833 | 0.804 |
| 151 | Transferrin + Ig heavy chain C region (T11749 + A46533) | 0.0786 | 0.8847 | 0.5434 | 0.3814 |
| 201 | Antithrombin + Complement component C9 ( | 0.5868 | 0.5314 | 0.5774 | 0.9455 |
| 220 | Hemopexin-like protein + Beta-actin ( | 0.2798 | 0.4227 | 0.5775 | 0.1481 |
| 224 | Hemopexin-like protein ( | 0.2104 | 0.9728 | 0.857 | 0.7601 |
| 227 | Hemopexin-like protein ( | 0.077 | 0.8458 | 0.5829 | 0.4513 |
| 249 | Serotransferrin II (TRF2SALSA) | 0.2894 | 0.5577 | 0.1483 | 0.0339 |
| 260 | Serum albumin 2 + Serum albumin 1 (ABONS2 + ABONS1) | 0.0291 | 0.1971 | 0.4523 | 0.8357 |
| 299 | Enolase ( | 0.1996 | 0.5102 | 0.1088 | 0.0032 |
| 313 | Pyruvatekinase ( | 0.0806 | 0.8639 | 0.0559 | 0.0039 |
| 317 | Enolase 1 (Alpha) ( | 0.1688 | 0.6918 | 0.0963 | 0.0042 |
| 326 | Alpha-2 enolase-1 ( | 0.1489 | 0.6904 | 0.0853 | 0.0061 |
| 328 | Alpha-2 enolase-1 ( | 0.2178 | 0.5131 | 0.1028 | 0.0013 |
| 342 | Serum albumin 2 (ABONS2) | 0.371 | 0.1541 | 0.8433 | 0.3281 |
| 357 | Serum albumin 2 + Complement factorB/C2-B (ABONS2 + | 0.1225 | 0.1539 | 0.71 | 0.6958 |
| 360 | Alpha-2 enolase-1 ( | 0.1997 | 0.7136 | 0.047 | 0.0002 |
| 368 | Serum albumin 2 + Serum albumin 1 (ABONS2 + ABONS1) | 0.0766 | 0.0806 | 0.7414 | 0.6659 |
| 381 | Alpha-2 enolase-1 + Creatine kinase ( | 0.0618 | 0.9464 | 0.0272 | 0.0041 |
| 386 | Aldolase ( | 0.1753 | 0.911 | 0.0229 | 0.0204 |
| 388 | Aldolase ( | 0.153 | 0.7466 | 0.0532 | 0.0752 |
| 391 | Muscle-type creatine kinase CKM1 ( | 0.0462 | 0.7088 | 0.004 | 0.0009 |
| 393 | Glyceraldehyde3-phosphate dehydrogenase ( | 0.1131 | 0.9435 | 0.0028 | 0.0002 |
| 394 | Aldolase A ( | 0.1324 | 0.9747 | 0.0067 | 0.0003 |
| 395 | Serotransferrin II (TRF2SALSA) | 0.0732 | 0.7892 | 0.4174 | 0.1811 |
| 440 | Alpha-2 enolase-1 (ABONS1) | 0.0534 | 0.8544 | 0.0097 | 0.0006 |
| 442 | Creatine kinase ( | 0.0536 | 0.9545 | 0.0334 | 0.0007 |
| 444 | Complement C3-1 + Cystein proteinase inhibitor protein ( | 0.3808 | 0.3852 | 0.8427 | 0.4569 |
| 450 | Serotransferrin II precursor (TRF2SALSA) | 0.0744 | 0.1147 | 0.8475 | 0.8393 |
| 463 | Glyceraldehyde3-phosphatedehydrogenase ( | 0.1712 | 0.8982 | 0.0287 | 0.0277 |
| 472 | Serum albumin 2 + Creatine kinase (ABONS2 + | 0.2774 | 0.2544 | 0.7464 | 0.3222 |
| 473 | Fructose-bisphosphate aldolase ( | 0.1771 | 0.8644 | 0.0292 | 0.0336 |
| 477 | Aldolase A ( | 0.1181 | 0.7005 | 0.0143 | 0.0255 |
| 479 | Glyceraldehyde 3-phosphatedehydrogenase ( | 0.0972 | 0.4788 | 0.0307 | 0.1032 |
| 493 | Glyceraldehyde 3-phosphatedehydrogenase ( | 0.2358 | 0.7868 | 0.0975 | 0.1501 |
| 494 | Glyceraldehyde 3-phosphate dehydrogenase ( | 0.271 | 0.8078 | 0.132 | 0.2332 |
| 499 | Proteasome ( | 0.1454 | 0.6439 | 0.0706 | 0.1262 |
| 500 | Aldolase A ( | 0.1836 | 0.7625 | 0.039 | 0.0693 |
| 509 | Serotransferrin II (TRF2SALSA) | 0.1302 | 0.1569 | 0.9378 | 0.5525 |
| 529 | Alpha-2 enolase-1 ( | 0.0105 | 0.1837 | 0.0004 | 0.0232 |
| 545 | Serotransferrin II (TRF2SALSA) | 0.01 | 0.1764 | 0.0002 | 0.0215 |
| 548 | Serumalbumin 1 ( | 0.381 | 0.1562 | 0.7586 | 0.2887 |
| 556 | Transferrin + Immunoglobulin light chain ( | 0.1617 | 0.063 | 0.7479 | 0.5452 |
| 565 | Hemopexin-like protein ( | 0.1514 | 0.0657 | 0.7578 | 0.6317 |
| 568 | Transferrin ( | 0.1625 | 0.079 | 0.6619 | 0.7647 |
| 575 | Apolipoprotein A-I + Ig light chain precursor (JH0472 + AAG18369) | 0.0124 | 0.115 | 0.3685 | 0.7495 |
| 584 | Malate dehydrogenase 1a ( | 0.0555 | 0.7354 | 0.0006 | 0.0001 |
| 586 | Apolipoprotein A-I (JH0472) | 0.1272 | 0.781 | 0.3957 | 0.1807 |
| 598 | Apolipoprotein A-I (JH0472) | 0.018 | 0.3991 | 0.3503 | 0.4654 |
| 602 | No significant identification | 0.0931 | 0.8462 | 0.0318 | 0.0005 |
| 608 | Triosephosphate isomerase ( | 0.0134 | 0.6271 | 0.0079 | 0.0029 |
| 613 | Serum albumin 2 (ABONS2) | 0.1367 | 0.6988 | 0.1639 | 0.0516 |
| 623 | Triosephosphate isomerase + Ig light chain ( | 0.1508 | 0.5987 | 0.0971 | 0.0068 |
| 624 | Triosephosphate isomerase ( | 0.0893 | 0.8886 | 0.1385 | 0.0628 |
| 626 | Ig light chain (AAG18369) | 0.1144 | 0.7554 | 0.1929 | 0.0606 |
| 627 | Triosephosphate isomerase + Ig light chain constant region ( | 0.0396 | 0.6455 | 0.0066 | 0.0115 |
| 628 | Triosephosphate isomerase ( | 0.0082 | 0.3003 | 0.0001 | 0.0047 |
| 642 | Apolipoprotein A-I (JH0472) | 0.4075 | 0.7725 | 0.675 | 0.6736 |
| 656 | Serotransferrin II (TRF2SALSA) | 0.0929 | 0.0296 | 0.7203 | 0.6526 |
| 668 | Apolipoprotein A-I (JH0472) | 0.2306 | 0.1865 | 0.8973 | 0.4736 |
| 669 | Apolipoprotein A-1 (JH0472) | 0.5808 | 0.4595 | 0.5278 | 0.3262 |
| 687 | Serotransferrin II (TRF2SALSA) | 0.1577 | 0.0552 | 0.8437 | 0.5952 |
| 702 | Prostaglandin D synthase ( | 0.1102 | 0.356 | 0.2959 | 0.4512 |
| 738 | Putative oncoprotein nm 23 ( | 0.1136 | 0.9017 | 0.0695 | 0.0056 |
| 741 | Nucleoside diphosphate kinase ( | 0.0736 | 0.8809 | 0.0467 | 0.007 |
Fig. 5Plotting spot 313 (pyruvate kinase) mean intensity and mean histopathological scoring of white muscle against sampling time points. Open circles plot histopathology scores and filled circles plot spot intensity at a given time point.